Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PI3K Gene Mutation”

80 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 80 results

Early research (Phase 1)Study completedNCT01613950
What this trial is testing

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Who this might be right for
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Ended earlyNCT04862143
What this trial is testing

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 2
Not applicableEnded earlyNCT01346579
What this trial is testing

Biomarkers in Tissue Samples From Older Women With Breast Cancer

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 505
Not applicableNot Yet RecruitingNCT07543250
What this trial is testing

A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Who this might be right for
Breast Cancer
xuliang 100
Large-scale testing (Phase 3)Study completedNCT03285802
What this trial is testing

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

Who this might be right for
Uterine Cancer
Greater Baltimore Medical Center 1
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Not applicableEnrolling By InvitationNCT06943313
What this trial is testing

Breast Cancer PET/CT Imaging With 68Ga-pAKTi

Who this might be right for
Breast CancersPIK3CA Mutation-Related TumorsPI3K Pathway Activated Tumors+1 more
Fudan University 20
Testing effectiveness (Phase 2)Looking for participantsNCT07405801
What this trial is testing

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 80
Early research (Phase 1)Looking for participantsNCT07383506
What this trial is testing

Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Who this might be right for
PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial Cancer+2 more
Cogent Biosciences, Inc. 90
Testing effectiveness (Phase 2)UnknownNCT04690725
What this trial is testing

TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss

Who this might be right for
Safety IssuesEfficacy, Self
Peking University People's Hospital 29
Large-scale testing (Phase 3)Active Not RecruitingNCT04208178
What this trial is testing

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Who this might be right for
Advanced HER2+Breast Cancer
Novartis Pharmaceuticals 19
Large-scale testing (Phase 3)Looking for participantsNCT07174336
What this trial is testing

Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Who this might be right for
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 800
Testing effectiveness (Phase 2)Study completedNCT01277757
What this trial is testing

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Who this might be right for
Recurrent Breast CarcinomaStage IIIB Breast CancerStage IIIC Breast Cancer+1 more
National Cancer Institute (NCI) 30
Large-scale testing (Phase 3)UnknownNCT05954442
What this trial is testing

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Who this might be right for
Triple Negative Breast CancerMetastatic Breast CancerMutation
Fudan University 203
Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 880
Testing effectiveness (Phase 2)Looking for participantsNCT05455619
What this trial is testing

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Who this might be right for
HR+/HER2-negative Breast CancerMetastatic Breast Cancer
SynDevRx, Inc. 52
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Early research (Phase 1)Active Not RecruitingNCT06239467
What this trial is testing

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Who this might be right for
Advanced CancerBreast CancerAdvanced Solid Tumors+1 more
OnKure, Inc. 200
Next Page